Related Experiment Video
Updated: Mar 25, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
1Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong Province, P.R. China. Fulw@mail.sysu.edu.cn.
Abstract:
Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately, only a fraction of patients with advanced tumors could benefit from anti-PD-1/PD-L1 therapy, while others still worsened. The key to this point is that there are no efficient biomarkers for screening anti-PD-1/PD-L1-sensitive patients. In this review, we aim at summarizing the latest advances of anti-PD-1/PDL1 immunotherapy and the potential predictive efficacy biomarkers to provide evidences for identifying anti-PD-1/PDL1- sensitive patients. The present article also includes the patent review coverage on this topic.
Insights
Cancer immunotherapy using programmed cell death 1 (PD-1) inhibitors shows promise, but lacks biomarkers to identify patients who will benefit from these treatments.
Area of Science:
- Oncology
- Immunology
- Biomarkers
Background:
- Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have emerged as a significant advancement in cancer immunotherapy.
- These therapies demonstrate durable antitumor effects, particularly in advanced malignancies.
Purpose of the Study:
- To review the latest advancements in anti-PD-1/PD-L1 immunotherapy.
- To summarize potential predictive biomarkers for patient selection in anti-PD-1/PD-L1 therapy.
- To provide evidence for identifying patients sensitive to these immunotherapies.
Main Methods:
- Literature review of recent studies on PD-1/PD-L1 inhibitors.
- Analysis of potential predictive biomarkers for immunotherapy response.
- Inclusion of a patent review on the topic.
Main Results:
- Only a subset of patients benefit from current anti-PD-1/PD-L1 therapies.
- Lack of efficient biomarkers hinders patient stratification.
- Emerging biomarkers show potential for predicting treatment efficacy.
Conclusions:
- Development of predictive biomarkers is crucial for optimizing anti-PD-1/PD-L1 immunotherapy.
- Identifying sensitive patients will improve treatment outcomes and resource allocation.
- Further research into biomarkers is warranted to enhance cancer treatment strategies.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
